ModernaCHIX:0QFD 67 14-Day RSI is 98.04 as of Jul. 12, 2026. GuruFocus rates CHIX:0QFD with a GF Score™ of 67/100 and a GF Value™ of €14.54 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,422 Biotechnology companies, Moderna ranks worse than 68.71% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-12), Moderna's 14-Day RSI is 98.04.
The industry rank for Moderna's 14-Day RSI or its related term are showing as below:
CHIX:0QFd's 14-Day RSI is ranked worse than 68.71% of 1422
companies
in the Biotechnology industry
Industry Median: 49.075
vs CHIX:0QFd: 98.04
Moderna (CHIX:0QFd) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Moderna 14-Day RSI Related Terms
CHIX:0QFD vs RPRX, ROIV, ONC: 14-Day RSI Comparison
For the Biotechnology subindustry, Moderna's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moderna's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Moderna's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna (CHIX:0QFD) has a 14-Day RSI of 98.04 as of Jul. 12, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Moderna and its competitors. According to the industry distribution chart, Moderna ranks #977 out of 1422 companies in the Biotechnology industry, placing it in the top 68.7%.
Is Moderna's 14-Day RSI too high?
Moderna's current 14-Day RSI is 98.04. The Biotechnology industry median 14-Day RSI is 49.08. Moderna's value of 98.04 is 99.8% above this industry median. Based on the distribution chart, Moderna ranks #977 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Moderna has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Moderna's 14-Day RSI compare to RPRX and ROIV?
According to the Biotechnology industry distribution chart, Moderna ranks #977 out of 1422 companies for 14-Day RSI. This places Moderna in the lower half of its industry. The industry median 14-Day RSI is 49.08. Moderna's value of 98.04 is 99.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.08, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moderna's current 14-Day RSI of 98.04 is 99.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Moderna and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moderna's current 14-Day RSI is 98.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Based on GuruFocus' analysis, Moderna (CHIX:0QFD) is currently considered Significantly Overvalued. The stock's GF Value™ is €14.54, compared to a current price of €70.49 — trading 384.8% above its estimated fair value. The current 14-Day RSI is 98.04 and 99.8% above the Biotechnology industry median of 49.08. Moderna's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current 14-Day RSI is 98.04 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moderna (CHIX:0QFD) Overvalued in 2026?
Based on GuruFocus' analysis, Moderna stock appears to be overvalued.
The current stock price of €70.49 is trading 384.8% above its estimated GF Value™ of €14.54.
GuruFocus considers Moderna to be Significantly Overvalued.
Key valuation signals for CHIX:0QFD:
14-Day RSI: 98.04
GF Value™: €14.54 vs. price of €70.49 (384.8% above fair value)
Industry Position: 99.8% above the Biotechnology median (#977 of 1422)
No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
67GF Score
Get the complete analysis for CHIX:0QFD
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:0QFD has been successfully added to your 